Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | SELL | P14151 | 1/20 | 0.44 |
| ▸ | SELP | P16109 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 2/20 | 0.41 |
| ▸ | DDO | Q99489 | 1/20 | 0.41 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.41 |
| ▸ | MPL | P40238 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4406397 | 0.80 | CNR2 (0.62) | CNR2GAAKDM4EHPGDHSD17B10 | |
| SCHEMBL16428858 | 0.77 | HPGD (0.57) | KDM4EHPGDHSD17B10ALDH1A1DAO | |
| SCHEMBL31423247 | 0.77 | CNR2 (0.40) | CNR2GAAKDM4EHPGDHSD17B10 | |
| SCHEMBL29415464 | 0.76 | DHODH (0.58) | CNR2GAAKDM4EHPGDHSD17B10 | |
| SCHEMBL2808417 | 0.76 | DHODH (0.58) | CNR2GAAKDM4EHPGDHSD17B10 | |
| SCHEMBL27348185 | 0.75 | DAO (0.64) | CNR2GAAKDM4EHPGDHSD17B10 | |
| SCHEMBL27443353 | 0.72 | DAO (0.64) | CNR2GAAKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL9264392 | 0.72 | DAO (0.64) | GAAKDM4EHPGDHSD17B10ALDH1A1 | |
| SCHEMBL31423163 | 0.72 | NOTUM (0.43) | CNR2GAAKDM4EHPGDHSD17B10 | |
| SCHEMBL4551849 | 0.71 | CNR2 (0.73) | CNR2GAAKDM4EHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030191069-A1 | 2-oxoquinoline compounds and pharmaceutical uses thereof | JAPAN TOBACCO, INC (JP) | 2003-10-09 | — | — | US | claimed |
| US-6509352-B1 | Selectively act on cannabinoid receptors, particularly on peripheral type cannabinoid receptors, and have fewer side effects on the central nervous system, having great immunosuppressive action, anti-inflammatory action or | JAPAN TOBACCO INC. (JP) | 2003-01-21 | — | — | US | claimed |
| EP-1142877-A1 | 2-OXOQUINOLINE COMPOUNDS AND MEDICINAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2001-10-10 | — | — | EP | claimed |
| EP-2130820-A1 | Antipruritics | SHIONOGI & CO., LTD. (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-20080312292-A1 | Antipruritics | YASUI KIYOSHI | 2008-12-18 | — | — | US | disclosed |
| US-20050101590-A1 | Cannabinoid receptor agonists | SHIONOGI & CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1477186-A1 | ANTIPRURITICS | SHIONOGI & CO., LTD. (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-6806276-B2 | SIDE EFFECT REDUCTION ON CENTRAL NERVOUS SYSTEM; IMMUNOSUPPRESSANTS; ANTIINFLAMMATORY AGENTS; ANTIALLERGENS | JAPAN TOBACCO INC. (JP) | 2004-10-19 | — | — | US | disclosed |
| US-20030232855-A1 | Therapeutic agent for allergic disease | JAPAN TOBACCO INC. | 2003-12-18 | — | — | US | disclosed |
| US-20030191069-A1 | 2-oxoquinoline compounds and pharmaceutical uses thereof | JAPAN TOBACCO, INC (JP) | 2003-10-09 | — | — | US | disclosed |
| US-6509352-B1 | Selectively act on cannabinoid receptors, particularly on peripheral type cannabinoid receptors, and have fewer side effects on the central nervous system, having great immunosuppressive action, anti-inflammatory action or | JAPAN TOBACCO INC. (JP) | 2003-01-21 | — | — | US | disclosed |
| CN-1337950-A | 2-oxoquinoline compounds and medicinal uses thereof | JAPAN TOBACCO INC (JP) | 2002-02-27 | — | — | CN | disclosed |
| EP-1142877-A1 | 2-OXOQUINOLINE COMPOUNDS AND MEDICINAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2001-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232855-A1 | Therapeutic agent for allergic disease | CNR1, CNR2, HRH4 | CNR2 2/4885GAA 3619/4885KDM4E 865/4885 |
| US-20050101590-A1 | Cannabinoid receptor agonists | CNR1, CNR2, OPRL1 | CNR2 2/4885GAA 4063/4885KDM4E 2840/4885 |
| US-20030191069-A1 | 2-oxoquinoline compounds and pharmaceutical uses thereof | CNR2, CNR1, OPRL1 | CNR2 1/4885GAA 4692/4885KDM4E 1771/4885 |
| US-20080312292-A1 | Antipruritics | CNR1, CNR2, OPRL1 | CNR2 2/4885GAA 3645/4885KDM4E 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.